RPS6KA2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1977787	1.00	20/20
SCHEMBL1978471	0.63	20/20
SCHEMBL1978175	0.60	20/20
SCHEMBL1978470	1.00	19/20
SCHEMBL1978542	1.00	19/20
SCHEMBL1978543	1.00	19/20
SCHEMBL1978727	1.00	19/20
SCHEMBL1978590	0.68	19/20
SCHEMBL1978769	0.61	19/20
SCHEMBL1977969	1.00	18/20
SCHEMBL1978457	1.00	18/20
SCHEMBL1978646	1.00	18/20
SCHEMBL1978648	1.00	18/20
SCHEMBL1978466	0.60	18/20
SCHEMBL1978467	0.60	18/20
SCHEMBL1978469	0.60	18/20
SCHEMBL1978187	1.00	17/20
SCHEMBL1978192	1.00	17/20
SCHEMBL1978536	1.00	17/20
SCHEMBL1977960	0.62	17/20

Clinical trials — most relevant to RPS6KA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse	PHASE2	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Therapeutic RSK1 Targeting in Myelofibrosis	PHASE1	RECRUITING
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
NK Cell Deregulation in HBV Patients	nan	ACTIVE_NOT_RECRUITING
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Exercise Effects on Cardiometabolic Health and Sestrin-2 in Hypertensive Obese Women	nan	NOT_YET_RECRUITING
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPS6KA2 binder may also engage these)

Protein	Name	Similarity
Q6PFQ0	—	1.000	Q6PFQ0 →
P10665	—	1.000	P10665 →
Q9WUT3	—	1.000	Q9WUT3 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	1.000	landscape →
P18654	—	1.000	P18654 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	0.999	landscape →
Q63531	—	0.999	Q63531 →
P10666	—	0.997	P10666 →
P18652	—	0.996	P18652 →
Q7TPS0	—	0.996	Q7TPS0 →
RPS6KA6	Ribosomal protein S6 kinase alpha-6	0.996	landscape →
Q21734	—	0.995	Q21734 →
A8XJQ6	—	0.994	A8XJQ6 →
P18653	—	0.994	P18653 →
Q5R4K3	—	0.994	Q5R4K3 →
Q18846	—	0.992	Q18846 →
Q5F3L1	—	0.992	Q5F3L1 →
Q6NW76	—	0.992	Q6NW76 →
PRKCD	Protein kinase C delta type	0.991	landscape →
RPS6KA5	Ribosomal protein S6 kinase alpha-5	0.991	landscape →
Q62074	—	0.991	Q62074 →
P34885	—	0.991	P34885 →
Q5RD00	—	0.991	Q5RD00 →
Q8R4V0	—	0.990	Q8R4V0 →
F1M7Y5	—	0.990	F1M7Y5 →
P11730	—	0.990	P11730 →
Q8BRK8	—	0.990	Q8BRK8 →
Q9NBK5	—	0.990	Q9NBK5 →
Q02956	—	0.990	Q02956 →
Q90XF2	—	0.990	Q90XF2 →